The Patent Finder

Regenxbio RS LLC

5 patents currently held · Updated Nov 17, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
May 2034
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

No maintenance fee falls due on this company's record before Nov 17, 2027.

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 5 of 5

PatentTitleStatus Expires Confidence
US 9,827,295Methods to Treat Mucopolysaccharide Type I or Deficiency in Alpha-L-Iduronidase Using a Recombinant Adeno-Associated Virus Encoding Alpha-L-Iduronidase
In force
 · High confidence
In forceHigh confidence
US 12,121,567Methods to Treat Mucopolysaccharidosis Type II or Deficiency in IDURONATE-2-Sulfatase Using a Recombinant Adeno-Associated Virus (AAV) Vector Encoding IDURONATE-2-Sulfatase
In force
 · Medium confidence
In forceMedium confidence
US 12,070,510Injection of Single-Stranded or Self-Complementary Adeno-Associated Virus 9 into the Cerebrospinal Fluid
In force
 · High confidence
In forceHigh confidence
US 11,613,739Treatment of Mucopolysaccharidosis II with Recombinant Human IDURONATE-2-Sulfatase (IDS) Produced by Human Neural or Glial Cells
In force
 · High confidence
In forceHigh confidence
US 11,986,515Treatment of Mucopolysaccharidosis II with Recombinant Human IDURONATE-2-Sulfatase (IDS)
In force
 · Medium confidence
In forceMedium confidence

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited